High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer
JCO Precision Oncology · 2024-03 · (8)
DOI: 10.1200/po.23.00348 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-03. Verfasst von Nicole Pfarr und 32 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, School of Medicine and Health, Technical University Munich, Munich, Germany. Hauptthemen laut MEDLINE: BRCA1 Protein, Ovarian Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency (HRD). The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, genomic instability (GI), and BRCA1/ 2 mutation status. Many of these assays have high potential to be broadly applied in clinical routine diagnostics in a time-effective decentralized manner. Here, we compare the performance of a multitude of alternative assays in comparison with Myriad myChoice in high-grade serous ovarian cancer (HGSOC). METHODS DNA from HGSOC samples was extracted from formalin-fixed paraffin-embedded tissue blocks of cases previously run with the Myriad myChoice assay, and GI was measured by multiple molecular assays (CytoSNP, AmoyDx, Illumina TSO500 HRD, OncoScan, NOGGO GISv1, QIAseq HRD Panel and whole genome sequencing), applying different bioinformatics algorithms. RESULTS Application of different assays to assess GI, including Myriad myChoice, revealed high concordance of the generated scores ranging from very substantial to nearly perfect fit, depending on the assay and bioinformatics pipelines applied. Interlaboratory comparison of assays also showed high concordance of GI scores. CONCLUSION Assays for GI assessment not only show a high concordance with each other but also in correlation with Myriad myChoice. Thus, almost all of the assays included here can be used effectively to assess HRD-associated GI in the clinical setting. This is important as PARPi treatment on the basis of these tests is compliant with European Medicines Agency approvals, which are methodologically not test-bound.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, School of Medicine and Health, Technical University Munich, Munich, Germany.
- Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Institute of Pathology, University Hospital Cologne, Cologne, Germany.
- Institute of Pathology, University Hospital Dresden, Dresden, Germany.
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Berlin Institute of Health, Berlin, Germany.
- Institute of Pathology and Hematopathology, Hamburg, Germany.
ORCID-Profile: Nicole Pfarr, Karin von Schwarzenberg, Dario Zocholl, Karsten Kleo, Eva-Maria Willing, Michael Menzel, Ulrich Lehmann, Stephan Bartels, Claudia Döring, Daniel Kazdal, Yann Christinat, Thomas McKee, David Horst, Reinhard Büttner
Zitieren
APA
Pfarr, N., von Schwarzenberg, K., Zocholl, D., Merkelbach-Bruse, S., Siemanowski, J., Mayr, E. M., Herold, S., Kleo, K., Heukamp, L. C., Willing, E. M., Menzel, M., Lehmann, U., Bartels, S., Chakraborty, S., Baretton, G., Demes, M. C., Döring, C., Kazdal, D., Budczies, J., …, & German HRD assay Harmonization Consortium (2024). High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00348
Vancouver
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, et al. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00348
BibTeX
@article{Pfarr2024,
author = {Pfarr, Nicole and von Schwarzenberg, Karin and Zocholl, Dario and Merkelbach-Bruse, Sabine and Siemanowski, Janna and Mayr, Eva-Maria and Herold, Sylvia and Kleo, Karsten and Heukamp, Lukas C and Willing, Eva-Maria and Menzel, Michael and Lehmann, Ulrich and Bartels, Stephan and Chakraborty, Shounak and Baretton, Gustavo and Demes, Melanie C and Döring, Claudia and Kazdal, Daniel and Budczies, Jan and Rad, Roland and Wild, Peter and Christinat, Yann and McKee, Thomas and Schirmacher, Peter and Horst, David and Büttner, Reinhard and Stenzinger, Albrecht and Sehouli, Jalid and Vollbrecht, Claudia and Hummel, Michael and Braicu, Elena I and Weichert, Wilko and German HRD assay Harmonization Consortium, German HRD assay Harmonization Consortium},
title = {High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.23.00348}
}
EUVIMED